Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of LCI699 in primary hyperaldosteronism
2007-005681-13Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of osilodrostat in primary aldosteronism (PA) and Secondary hypertension, sponsored by Novartis. Primary endpoints: Hemodynamic effects on mean 24-hour systolic blood pressure, Pharmacodynamic profile (blood pressure, electrolytes, hormones) and 1 more. Started Feb 2008; status: completed.
02
Drugs
osilodrostat
03
Conditions
primary aldosteronism (PA)Secondary hypertension
Beyond the preview
Go deeper on 2007-005681-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005681-13.